Table 1.
Descriptions of used databases
| Database | Ethnicity | Total sample size (asthma case count) | Male percentage | Median ageg | Usage |
|---|---|---|---|---|---|
| MarketScan (select age ≥15)a | White (78.3%), Black (14.5%)f | 84,315,387 (6,048,247) | 44.8% | 41 (29–53) | Asthma subgroup identification |
| UK Biobankb | British white | 305,098 (44,383) | 45.7% | 59 (51–64) | GWAS discovery, and phenotype association analysis |
| Irish white | 22,600 (3,186) | 41.9% | 57 (49–63) | Replication of GWAS findings via meta-analysis | |
| African, Caribbean | 6,833 (998) | 40.5% | 51 (46–58) | ||
| BioVUc | White | 16,060 (1,668) | 50.3% | 61 (51–71) | |
| BioBank Japand | East Asian | 194,413 (3,368) | 54.1% | 65 (55–73) | |
| UChicago RNAseqe | White (37.1%), Black (58.6%) | 70 (42) | 32.9% | 38 (27–50) | Differential gene expression validation |
aThe MarketScan insurance claims database in the US, including diagnosis records.
bNational health database in the UK, including diagnosis records and genotype data.
cPatient-based registry of Vanderbilt University Medical Center, including diagnosis records and genotype data.
dPatient-based registry in Japan, including diagnosis records and genotype data.
eRNAseq transcriptome profiles of bronchial epithelial cells of patients enrolled in the University of Chicago.
fImputed percentage based on county-level distributions of race.
gValues in parentheses are interquartile ranges given in years.